Acceptance Code: HTA338

Tracing the Shift in Payer Evidence Expectations: A Review of AMCP Format Updates (2016-2024)

Amit Dang, **Dimple Dang**, Tanvi Laghate, Vallish BN

MarksMan Healthcare Communications (Hyderabad, India)

Background

- The AMCP Format (since 2000) has been the standard for evidence presentation required for US formulary decisions, guiding manufacturers in sharing clinical, comparative effectiveness, and economic data with payers.[1]
- Version 4.0 (2016) marked a major format transformation, introducing recommendations on biosimilars, diagnostics, comparative effectiveness, and pre-approval evidence; however, remaining text-heavy and static.[2]
- Version 4.1 (2019-2020) addressed digital compatibility, introduced modular dossiers (unapproved products/uses), and integrated real-world evidence (RWE) guidance for broader bidirectional communication.[3]
- The latest format, i.e., AMCP Format for Formulary Submissions 5.0 (2024), emphasizes concise communication, RWE integration, digital therapeutics, while addressing health disparities, and real-time engagement.[4]

Objectives

- To review the progression of updates in the AMCP Format from Version 4.0 to Submissions 5.0, examining structural, content, and strategic modifications, and their implications for market access communications and payer engagement.

Methodology

- A targeted review of official AMCP guidance documents (Versions 4.0, 4.1, 5.0) was performed, along with insights from AMCP Partnership Forums, JMCP publications, and payer commentaries (2016-2024).
- **Changes were evaluated across five key domains:**
  - Dossier structure and modularity
  - Digital and RWE integration
  - Inclusion of underrepresented populations
  - Pre-approval information exchange (PIE)
  - Evidence presentation (brevity, visualization)

Results

Comparative Evolution of AMCP Format (2016–2024)

Parameter	AMCP 4.0 (2016)	AMCP 4.1 (2019-20)	AMCP 5.0 (2024)
Focus	Standardized clinical & economic data	Digital compatibility & early RWE inclusion	RWE, equity, DTx, PIE
Template	Static, text-heavy	Modular, flexible	Concise, visual, hyperlink-enabled
Dossier Types	Single	3 types (Approved, Unapproved, Unapproved Use)	Comprehensive with DTx-specific guidance
New Additions	–	Early engagement, PIE	Health disparities, pharmaco equity, brevity
Key Challenge	Limited real-world adaptability	Transition to digital	Managing brevity + evidence richness

Shift in Key Evidence Priorities



AMCP 5.0 Core Principles



From AMCP 5.0 Updates ⟶ Practical Implications

Discussion

- AMCP 5.0 indicates a shift from static, text-heavy dossiers to dynamic, digital, and equity-driven evidence ecosystems.[4]
- Manufacturers must now develop "living dossiers" incorporating real-time RWE, diversity data, and iterative updates to exhibit post-marketing evidence.[4]
- Guidance emphasizes bidirectional engagement between manufacturers and healthcare decision makers (HCDMs), facilitating earlier, data-informed access discussions.[4]
- Evidence from AMCP Partnership Forums and JMCP publications supports this change, underscoring payer preference for concise, structured dossiers and integrated RWE to improve review quality and decision speed.[4-8]
- Findings from literature also report that digitally enhanced dossiers with integrated visual data result in faster, higher-quality payer assessments and enhanced formulary placement efficiency.[9-12]
- For HEOR and medical-writing professionals, this evolution demands new skill sets in:[4, 13]
  - Data visualization and concise evidence storytelling
  - Digital-first dossier development
  - Equity-focused communication frameworks
- **Looking ahead**
  - Evidence Volume & Standardization: With increasing submissions, ensuring data quality, consistency, and interoperability will be crucial.
  - AI & Automation: Future AMCP updates can implement AI-assisted evidence synthesis and automated dossier updates.[14]
  - Interoperability: Aligning with payer IT systems and electronic health records (EHR)-integrated reviews will be critical for real-time access.[14, 15]
  - Global Harmonization: Coordination across AMCP, EU-HTA, and global value frameworks will facilitate cross-market efficiency.[15]
- **Future AMCP 6.0 Vision:**
  - Integrate metadata tagging and machine-readable formats for quicker review.
  - Support interactive, dashboard-based dossiers linking RWE and budget data.
  - Develop pharmaco-equity measures and outcome diversity tracking.

Conclusion

- AMCP 5.0 represents a paradigm shift toward concise, digital, payer-receptive evidence communication.
- It integrates guidance on DTx, RWE, PIE, and health equity, indicating payer expectations for relevance in the real world.
- The format also supports early, evidence-based engagement with HCDMs to enhance decision efficiency.
- It is essential to align dossier strategy with HEOR and evidence generation for future-ready market access.

References

1. https://www.ispor.org/docs/default-source/intl2024/we-need-to-talk---format-5.pdf?sfvrsn=86db4c35_0
2. https://www.amcp.org/press-releases/academy-releases-version-40-amcp-format-formulary-submissions
3. https://www.amcp.org/sites/default/files/2019-12/AMCP_Format%204.1_1219_final.pdf
4. https://www.amcp.org/sites/default/files/2024-04/AMCP-Format-5.0-JMCP-web_0.pdf
5. Johnson A, et al. J Manag Care Spec Pharm. 2024;30(11):1318-326.
6. AMCP Partnership Forum. J Manag Care Spec Pharm. 2020 May;26(5):674-681.
7. JMCP. J Manag Care Spec Pharm. 2022;28(7):804-10.
8. https://www.amcp.org/policy-advocacy/legislative-regulatory-issues/pre-approval-information-exchange
9. Watkins JB, et al. J Manag Care Spec Pharm. 2020 Jun;26(6):696-700.
10. Dodda S, et al. J Manag Care Spec Pharm. 2023 Mar;29(3):245-250.
11. Niyazov A, et al. Front. Public Health. 2018; 6:304.
12. https://www.ispor.org/docs/default-source/cti-meeting-21021-documents/bd271cf8-1881-4ff7-ab35-f6e0656d3390.pdf?sfvrsn=423698e5_0
13. https://petauri.com/insights/amcp-dossiers/
14. https://www.amcp.org/blog/ai-and-future-managed-care-key-takeaways-amcps-ai-pre-conference
15. AMCP Partnership Forum. J Manag Care Spec Pharm. 2017 Jan;23(1):105-112.

Poster presented at ISPOR EU 2025; Glasgow, Scotland, UK; 9-12 November 2025